Patents by Inventor Adel Remond RIZKALA

Adel Remond RIZKALA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL USE
    Publication number: 20220133694
    Abstract: The present invention relates to novel methods and pharmaceutical compositions for the treatment of heart failure in a patient.
    Type: Application
    Filed: July 9, 2021
    Publication date: May 5, 2022
    Inventors: Adel Remond RIZKALA, Victor Chengwei SHI, Fabian CHEN
  • Sacubitril-valsartan dosage regimen for treating heart failure
    Patent number: 11058667
    Abstract: The present invention relates to sacubitril-valsartan dosage regimens for the treatment of heart failure in a patient.
    Type: Grant
    Filed: May 9, 2016
    Date of Patent: July 13, 2021
    Assignee: Novartis AG
    Inventors: Adel Remond Rizkala, Victor Chengwei Shi, Fabian Chen
  • NEW USE
    Publication number: 20210077461
    Abstract: The present invention relates to methods and pharmaceutical compositions for the prevention or in delaying time to first occurrence of mortality, in particular cardiovascular death, and/or of cardiovascular hospitalizations in a patient suffering from chronic systolic heart failure, comprising administration of a therapeutically effective amount, or a prophylactically effective amount, of an Angiotensin Receptor Neprilysin inhibitor (ARNi) or of a combination of an Angiotensin Receptor Blocker (ARB) with a Neutral Endopeptidase inhibitor (NEPi) or with a NEPi pro-drug to said patient.
    Type: Application
    Filed: November 24, 2020
    Publication date: March 18, 2021
    Inventors: Victor Chengwei SHI, Martin LEFKOWITZ, Adel Remond RIZKALA
  • SACUBITRIL-VALSARTAN DOSAGE REGIMEN FOR TREATING HEART FAILURE
    Publication number: 20180125820
    Abstract: The present invention relates to sacubitril-valsartan dosage regimens for the treatment of heart failure in a patient.
    Type: Application
    Filed: May 9, 2016
    Publication date: May 10, 2018
    Inventors: Adel Remond Rizkala, Victor Chengwei SHI, Fabian CHEN
  • NEW USE
    Publication number: 20160213646
    Abstract: The present invention relates to methods and pharmaceutical compositions for the prevention or in delaying time to first occurrence of mortality, in particular cardiovascular death, and/or of cardiovascular hospitalizations in a patient suffering from chronic systolic heart failure, comprising administration of a therapeutically effective amount, or a prophylactically effective amount, of an Angiotensin Receptor Neprilysin inhibitor (ARNi) or of a combination of an Angiotensin Receptor Blocker (ARB) with a Neutral Endopeptidase inhibitor (NEPi) or with a NEPi pro-drug to said patient.
    Type: Application
    Filed: August 26, 2014
    Publication date: July 28, 2016
    Applicant: NOVARTIS AG
    Inventors: Victor Chengwei SHI, Martin LEFKOWITZ, Adel Remond RIZKALA